Analyzing Aclarion (NASDAQ:ACON) & MDxHealth (NASDAQ:MDXH)

MDxHealth (NASDAQ:MDXH) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Profitability

This table compares MDxHealth and Aclarion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDxHealth	-50.54%	-987.86%	-29.15%
Aclarion	-10,967.15%	-910.84%	-218.13%

Volatility and Risk

MDxHealth has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.

Earnings and Valuation

This table compares MDxHealth and Aclarion”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$80.74 million	0.05	-$43.10 million	N/A	N/A
Aclarion	$53,947.00	26.91	-$4.91 million	N/A	N/A

Aclarion has lower revenue, but higher earnings than MDxHealth.

Analyst Ratings

This is a breakdown of current ratings and target prices for MDxHealth and Aclarion, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	0	0	3	0	3.00
Aclarion	0	0	1	0	3.00

MDxHealth currently has a consensus price target of $7.50, suggesting a potential upside of 197.62%. Aclarion has a consensus price target of $1.50, suggesting a potential upside of 747.46%. Given Aclarion’s higher probable upside, analysts plainly believe Aclarion is more favorable than MDxHealth.

Insider and Institutional Ownership

7.5% of Aclarion shares are held by institutional investors. 1.7% of MDxHealth shares are held by insiders. Comparatively, 22.3% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Aclarion beats MDxHealth on 6 of the 11 factors compared between the two stocks.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.